This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Nuclear receptor subfamily 5 group A member 2 (NR5A2; LRH-1)

Mouse and in vitro studies identified an LRH-1 antagonist that could be useful for treating cancer. In in vitro binding studies, the compound bound LHR-1 with a Kd value of about 1.8 µM. In human cancer cells, the compound inhibited proliferation of LHR-1-positive cell lines. Next steps could include evaluating the LRH-1 antagonist in mouse xenograft models.

SciBX 6(23); doi:10.1038/scibx.2013.573
Published online June 13, 2013

Patent and licensing status not available

Benod, C. et al. J. Biol. Chem.; published online May 10, 2013;
doi:10.1074/jbc.M112.411686
Contact: Robert Fletterick, University of California, San Francisco, Calif.
e-mail:
robert.fletterick@ucsf.edu